DNA Diagnostics Market Size, Share And Trends Report, 2033
The global DNA diagnostics market size was estimated at USD 10.69 billion in 2023 and is projected to hit around USD 16.05 billion by 2033, growing at a CAGR of 4.15% during the forecast period from 2024 to 2033.
Key Takeaways:
DNA Diagnostics Market Growth
The growth of the market is attributed to an increase in the incidence of genetic, infectious, and chronic diseases as well as decreasing prices of genetic sequencing technologies aided by the growing adoption of precision medicine diagnostic techniques. The market is primarily driven by DNA profiling, which aims to enhance the understanding of disease predisposition and potential adverse reactions associated with existing or under-clinical development drugs. The increasing significance of early diagnosis and prevention, alongside the growing demand for DNA tests in areas such as pharmacogenomics and cancer genetic testing, contributes significantly to market growth.
The growing demand for DNA diagnostics is expected to be driven by various factors. One such factor is the increasing implementation of personalized medicine applications for the treatment of chronic disorders. This approach emphasizes tailoring medical interventions based on an individual's genetic profile, leading to a growing need for HLA typing and DNA identification for therapy. Furthermore, the demand for DNA diagnostics is expected to be fueled by advancements in technology that enable the commercialization of next-generation diagnostic and testing solutions utilizing genetic analysis. These hi-tech advancements offer more advanced and precise tools for genetic analysis, contributing to improved diagnostic accuracy and expanded testing capabilities. Thus, collectively, these factors are anticipated to increase growth.
With the rising demand for newborn and pre-natal screening aimed at detecting congenital abnormalities, an increased focus on early detection and intervention drives the need for DNA testing in these screening programs. Furthermore, the application of DNA testing as a crucial step in biobanking services, particularly in cord blood banking, contributes to sector growth. Physicians’ higher inclination towards genetic testing to determine patients’ health at different stages of disease development is another factor expected to fuel demand in the coming years.
However, one of the major factors hampering the market’s growth is the high cost associated with the development of these diagnostic tests. The research and development (R&D) efforts related to introducing new techniques and implementing them in practice are expensive and have a high cost associated with them. These costs can be a barrier for some companies and hinder overall industry growth.
Moreover, stringent government regulations surrounding DNA prototyping and the need for a clear reimbursement structure are anticipated to pose obstacles for new market entrants. Compliance with these regulations and navigating the reimbursement landscape can be complex and time-consuming, discouraging potential players from entering the market. Overall, while the market for DNA diagnostics exhibits significant potential, these challenges need to be addressed to ensure sustained growth and a favorable environment for innovation and competition.
DNA Diagnostics Market Report Scope
| Report Attribute | Details |
| Market Size in 2024 | USD 11.13 Billion |
| Market Size by 2033 | USD 16.05 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 4.15% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Technology, application, region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | GE Healthcare; Abbott, Beckman Coulter Inc.; Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific Inc.; Illumina Inc.; Cepheid; Hologic Inc.; Siemens Healthcare GmbH; F. Hoffmann-La Roche; QIAGEN; Agilent Technologies Inc. |
Technology Insights
In terms of technology, the PCR-based diagnostics segment held the largest revenue share of 52.03% in 2023. The dominance of the segment is attributed to the widespread market usage and high availability of products owing to the presence of a significant number of players offering PCR-based diagnostics in the market. Moreover, PCR offers high sensitivity and specificity, allowing for the detection of even small amounts of DNA in a sample. This makes it particularly useful in diagnosing infectious diseases and genetic disorders and identifying genetic variations associated with cancer and other diseases. In May 2023, Sensible Diagnostics, a Los Angeles-based organization, announced that they are targeting the introduction of a 10-minute point-of-care PCR system by early next year. Thus, these factors are anticipated to bolster the growth of PCR-based diagnostic technology, thereby fueling the market growth.
Next-generation sequencing (NGS)-based diagnosis is anticipated to witness the fastest CAGR of 7.98% over the forecast period owing to the development of innovative and breakthrough advancements in the market. NGS platforms have the ability to process multiple samples in parallel, allowing for high-throughput sequencing. This increased efficiency makes NGS suitable for applications such as whole-genome sequencing, exome sequencing, targeted gene panels, and transcriptome analysis. Moreover, NGS-based Diagnostics play a crucial role in advancing precision medicine approaches. By providing detailed genetic information, NGS enables personalized treatment decisions, prognostic assessments, and the identification of targeted therapies based on an individual's genomic profile. Thus, the availability of various platforms for sequencing and analysis of DNA data that result in efficient, highly accurate, and rapid diagnosis is further expected to fuel the growth of the segment.
Application Insights
Based on application, cancer genetics tests dominated the market in 2023 with a revenue share of 30.58% in 2023. The dominance of the segment can be attributed to the growing prevalence of cancer globally, increased adoption of personalized medicine, and growing technological advancements in DNA sequencing technology. The development of advanced DNA sequencing technologies, such as NGS, has made cancer genetic testing more accessible, efficient, and cost-effective. These technologies allow for comprehensive analysis of multiple genes simultaneously, increasing the accuracy and efficiency of genetic testing for cancer.
Certain genetic mutations are known to be strongly associated with hereditary cancer syndromes, such as BRCA1 and BRCA2 mutations in breast and ovarian cancer. Cancer genetics tests can identify these mutations, enabling proactive screening and preventive measures for individuals with a higher genetic predisposition to cancer. Thus, these factors are anticipated to boost the cancer genetics tests application, thereby fueling the DNA diagnostic market over the forecast period.
Infectious diseases DNA testing is anticipated to grow at the fastest CAGR of 4.51% over the forecast period. DNA testing methods have proven to be highly important in infectious disease diagnosis and clinical confirmation. This application segment has generated substantial revenue due to the availability of various products designed for diseases such as HBV, HCV, HIV, TB, CT/NG, HPV, and MRSA. In addition, the increasing utilization of DNA diagnostics in chronic oncology cases and related abnormalities is expected to drive significant growth in the oncology diagnostics & histopathology segment in the near future. The adoption of sequencing technology for tumor detection and biomarker analysis is another factor contributing to the overall market growth throughout the forecast period.
Regional Insights
North America dominated the DNA diagnostics market in 2023 with a revenue share of 43.45%. The presence of sophisticated healthcare infrastructure, strong government initiatives, proactive funding for DNA testing research, and the high prevalence of chronic diseases are the major drivers for market growth in this region. Furthermore, North America has seen widespread adoption of genetic testing for various purposes, such as disease risk assessment, pharmacogenomics, prenatal screening, and ancestry testing. The availability of advanced laboratory facilities, favorable reimbursement policies, and a large population base with access to healthcare contribute to the region's dominance in the DNA diagnostic market.
Asia Pacific is expected to witness the fastest CAGR of 6.24% from 2024 to 2033 due to rising research & development incentives offered by the government in developing economies such as China and India, which enable R&D and commercialization of technologically innovative products. Moreover, the high accessibility of the target population owing to the prevalence of chronic diseases is also anticipated to supplement growth in the coming years. In addition, the region has witnessed significant advancements in DNA sequencing technologies, such as NGS. These technological developments have made DNA diagnostics more accessible, efficient, and cost-effective, thereby driving market growth.
Key Companies & Market Share Insights
Market participants are involved in R&D for the introduction of rapid testing methods that provide reproducible and accurate results and aid in the diagnosis of genetic abnormalities. For instance, in April 2023, Agilent Technologies Inc. announced the launch of SureSelect Cancer CGP Assay, which is particularly devised for somatic variant profiling for a broad wide range of solid tumor forms. Furthermore, these entities are also engaged in developing and updating their databases for mining and comparing DNA specimens to help law enforcement in solving criminal cases. Some prominent players in the global DNA diagnostics market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the DNA Diagnostics market.
By Technology
By Application
By Region
Chapter 1. DNA Diagnostics Market: Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Technology Segment
1.1.1.2. Application Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. nova one advisor Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. DNA Diagnostics Market: Executive Summary
2.1. Market Snapshot
2.2. Technology and Application Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. DNA Diagnostics Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.5. Market Restraint Analysis
3.6. Porter’s Five Forces Analysis
3.7. PESTLE Analysis
3.8. Pipeline Analysis
Chapter 4. DNA Diagnostics Market: Technology Estimates & Trend Analysis
4.1. DNA Diagnostics Market: Technology Movement Analysis
4.2. Microarrays-based Diagnostics
4.2.1. Microarrays-based Diagnostics Market Estimates And Forecasts, 2021 - 2033
4.3. PCR-based Diagnostics
4.3.1. PCR-based Diagnostics Market Estimates And Forecasts, 2021 - 2033
4.4. In-Situ Hybridization Diagnostics
4.4.1. In-Situ Hybridization Diagnostics Market Estimates And Forecasts, 2021 - 2033
4.5. NGS DNA Diagnosis
4.5.1. NGS DNA Diagnosis Market Estimates And Forecasts, 2021 - 2033
Chapter 5. DNA Diagnostics Market: Application Estimates & Trend Analysis
5.1. DNA Diagnostics Market: Application Movement Analysis
5.2. Cancer Genetics Tests
5.2.1. Cancer Genetics Tests Market Estimates and Forecasts, 2021 - 2033
5.3. Infectious Diseases DNA Testing
5.3.1. Infectious Diseases DNA Testing Market Estimates and Forecasts, 2021 - 2033
5.3.2. HBV Diagnostic
5.3.2.1. HBV Diagnostic Market Estimates and Forecasts, 2021 - 2033
5.3.3. HCV Diagnostic
5.3.3.1. HCV Diagnostic Market Estimates and Forecasts, 2021 - 2033
5.3.4. HIV Diagnostic
5.3.4.1. HIV Diagnostic Market Estimates and Forecasts, 2021 - 2033
5.3.5. TB Diagnostic
5.3.5.1. TB Diagnostic Market Estimates and Forecasts, 2021 - 2033
5.3.6. CT/NG Diagnostic
5.3.6.1. CT/NG Diagnostic Market Estimates and Forecasts, 2021 - 2033
5.3.7. HPV Diagnostic
5.3.7.1. HPV Diagnostic Market Estimates and Forecasts, 2021 - 2033
5.3.8. MRSA Diagnostic
5.3.8.1. MRSA Diagnostic Market Estimates and Forecasts, 2021 - 2033
5.3.9. Others
5.3.9.1. Others Market Estimates and Forecasts, 2021 - 2033
5.4. Newborn Genetic Screening
5.4.1. Newborn Genetic Screening Market Estimates and Forecasts, 2021 - 2033
5.5. Preimplantation & Reproductive Diagnosis
5.5.1. Preimplantation & Reproductive Diagnosis Market Estimates and Forecasts, 2021 - 2033
5.6. Non-Infectious Diseases DNA Testing
5.6.1. Non-Infectious Diseases DNA Testing Market Estimates and Forecasts, 2021 - 2033
5.6.2. Cardiovascular Diseases
5.6.2.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033
5.6.3. CNS & PNS Related
5.6.3.1. CNS & PNS Related Market Estimates and Forecasts, 2021 - 2033
5.6.4. Skeletal, Connective, Ectodermal & Dermal DNA Testing
5.6.4.1. Skeletal, Connective, Ectodermal & Dermal DNA Testing Market Estimates and Forecasts, 2021 - 2033
5.6.5. Lung, Kidney, Liver & GT Related
5.6.5.1. Lung, Kidney, Liver & GT Related Market Estimates and Forecasts, 2021 - 2033
5.6.6. Sensory Diseases
5.6.6.1. Sensory Diseases Market Estimates and Forecasts, 2021 - 2033
5.7. Prenatal DNA Carrier Screening
5.7.1. Prenatal DNA Carrier Screening Market Estimates and Forecasts, 2021 - 2033
5.8. Pharmacogenomics/Drug Metabolism
5.8.1. Pharmacogenomics/Drug Metabolism Market Estimates and Forecasts, 2021 - 2033
5.9. Hematology & Immunology/Identity Diagnostics & Forensics
5.9.1. Hematology & Immunology/Identity Diagnostics & Forensics Market Estimates and Forecasts, 2021 - 2033
5.10. Others
5.10.1. Others Market Estimates and Forecasts, 2021 - 2033
Chapter 6. DNA Diagnostics Market: Regional Business Analysis
6.1. Regional Market Snapshot
6.2. North America
6.2.1. North America DNA Diagnostics Market Estimates And Forecast, 2021 - 2033
6.2.2. U.S.
6.2.2.1. U.S. DNA Diagnostics Market, 2021 - 2033
6.2.2.2. Key Country Dynamics
6.2.2.3. Regulatory Framework
6.2.2.4. Reimbursement Scenario
6.2.2.5. Competitive Scenario
6.2.3. CANADA
6.2.3.1. Canada DNA Diagnostics Market, 2021 - 2033
6.2.3.2. Key Country Dynamics
6.2.3.3. Regulatory Framework
6.2.3.4. Reimbursement Scenario
6.2.3.5. Competitive Scenario
6.3. Europe
6.3.1. Europe DNA Diagnostics Market, 2021 - 2033
6.3.2. UK
6.3.2.1. UK DNA Diagnostics Market, 2021 - 2033
6.3.2.2. Key Country Dynamics
6.3.2.3. Regulatory Framework
6.3.2.4. Reimbursement Scenario
6.3.2.5. Competitive Scenario
6.3.3. GERMANY
6.3.3.1. Germany DNA Diagnostics Market, 2021 - 2033
6.3.3.2. Key Country Dynamics
6.3.3.3. Regulatory Framework
6.3.3.4. Reimbursement Scenario
6.3.3.5. Competitive Scenario
6.3.4. SPAIN
6.3.4.1. Spain DNA Diagnostics Market, 2021 - 2033
6.3.4.2. Key Country Dynamics
6.3.4.3. Regulatory Framework
6.3.4.4. Reimbursement Scenario
6.3.4.5. Competitive Scenario
6.3.5. FRANCE
6.3.5.1. France DNA Diagnostics Market, 2021 - 2033
6.3.5.2. Key Country Dynamics
6.3.5.3. Regulatory Framework
6.3.5.4. Reimbursement Scenario
6.3.5.5. Competitive Scenario
6.3.6. ITALY
6.3.6.1. Italy DNA Diagnostics Market, 2021 - 2033
6.3.6.2. Key Country Dynamics
6.3.6.3. Regulatory Framework
6.3.6.4. Reimbursement Scenario
6.3.6.5. Competitive Scenario
6.3.7. DENMARK
6.3.7.1. Denmark DNA Diagnostics Market, 2021 - 2033
6.3.7.2. Key Country Dynamics
6.3.7.3. Regulatory Framework
6.3.7.4. Reimbursement Scenario
6.3.7.5. Competitive Scenario
6.3.8. SWEDEN
6.3.8.1. Sweden DNA Diagnostics Market, 2021 - 2033
6.3.8.2. Key Country Dynamics
6.3.8.3. Regulatory Framework
6.3.8.4. Reimbursement Scenario
6.3.8.5. Competitive Scenario
6.3.9. NORWAY
6.3.9.1. Norway DNA Diagnostics Market, 2021 - 2033
6.3.9.2. Key Country Dynamics
6.3.9.3. Regulatory Framework
6.3.9.4. Reimbursement Scenario
6.3.9.5. Competitive Scenario
6.4. Asia Pacific
6.4.1. Asia Pacific DNA Diagnostics Market, 2021 - 2033
6.4.2. JAPAN
6.4.2.1. Japan DNA Diagnostics Market, 2021 - 2033
6.4.2.2. Key Country Dynamics
6.4.2.3. Regulatory Framework
6.4.2.4. Reimbursement Scenario
6.4.2.5. Competitive Scenario
6.4.3. CHINA
6.4.3.1. China DNA Diagnostics Market, 2021 - 2033
6.4.3.2. Key Country Dynamics
6.4.3.3. Regulatory Framework
6.4.3.4. Reimbursement Scenario
6.4.3.5. Competitive Scenario
6.4.4. INDIA
6.4.4.1. India DNA Diagnostics Market, 2021 - 2033
6.4.4.2. Key Country Dynamics
6.4.4.3. Regulatory Framework
6.4.4.4. Reimbursement Scenario
6.4.4.5. Competitive Scenario
6.4.5. SOUTH KOREA
6.4.5.1. South Korea DNA Diagnostics Market, 2021 - 2033
6.4.5.2. Key Country Dynamics
6.4.5.3. Regulatory Framework
6.4.5.4. Reimbursement Scenario
6.4.5.5. Competitive Scenario
6.4.6. THAILAND
6.4.6.1. Thailand DNA Diagnostics Market, 2021 - 2033
6.4.6.2. Key Country Dynamics
6.4.6.3. Regulatory Framework
6.4.6.4. Reimbursement Scenario
6.4.6.5. Competitive Scenario
6.4.7. AUSTRALIA
6.4.7.1. Australia DNA Diagnostics Market, 2021 - 2033
6.4.7.2. Key Country Dynamics
6.4.7.3. Regulatory Framework
6.4.7.4. Reimbursement Scenario
6.4.7.5. Competitive Scenario
6.5. Latin America
6.5.1. Latin America DNA Diagnostics Market, 2021 - 2033
6.5.2. BRAZIL
6.5.2.1. Brazil DNA Diagnostics Market, 2021 - 2033
6.5.2.2. Key Country Dynamics
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement Scenario
6.5.2.5. Competitive Scenario
6.5.3. MEXICO
6.5.3.1. Mexico DNA Diagnostics Market, 2021 - 2033
6.5.3.2. Key Country Dynamics
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement Scenario
6.5.3.5. Competitive Scenario
6.5.4. ARGENTINA
6.5.4.1. Argentina DNA Diagnostics Market, 2021 - 2033
6.5.4.2. Key Country Dynamics
6.5.4.3. Regulatory Framework
6.5.4.4. Reimbursement Scenario
6.5.4.5. Competitive Scenario
6.6. MEA
6.6.1. MEA DNA Diagnostics Market, 2021 - 2033
6.6.2. SOUTH AFRICA
6.6.2.1. South Africa DNA Diagnostics Market, 2021 - 2033
6.6.2.2. Key Country Dynamics
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement Scenario
6.6.2.5. Competitive Scenario
6.6.3. SAUDI ARABIA
6.6.3.1. Saudi Arabia DNA Diagnostics Market, 2021 - 2033
6.6.3.2. Key Country Dynamics
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement Scenario
6.6.3.5. Competitive Scenario
6.6.4. UAE
6.6.4.1. UAE DNA Diagnostics Market, 2021 - 2033
6.6.4.2. Key Country Dynamics
6.6.4.3. Regulatory Framework
6.6.4.4. Reimbursement Scenario
6.6.4.5. Competitive Scenario
6.6.5. KUWAIT
6.6.5.1. Kuwait DNA Diagnostics Market, 2021 - 2033
6.6.5.2. Key Country Dynamics
6.6.5.3. Regulatory Framework
6.6.5.4. Reimbursement Scenario
6.6.5.5. Competitive Scenario
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.2.1. NEW PRODUCT LAUNCH
7.2.2. PARTNERSHIPS
7.2.3. ACQUISITION
7.2.4. COLLABORATION
7.2.5. FUNDING
7.3. Key Company Market Share Analysis, 2022
7.4. Company Heat Map Analysis
7.5. Company Profiles
7.5.1. GE HEALTHCARE
7.5.1.1. Company Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. ABBOTT
7.5.2.1. Company Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. BECKMAN COULTER INC.
7.5.3.1. Company Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. BIO-RAD LABORATORIES, INC.
7.5.4.1. Company Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. THERMO FISHER SCIENTIFIC INC.
7.5.5.1. Company Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. ILLUMINA INC.
7.5.6.1. Company Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. CEPHEID
7.5.7.1. Company Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. CEPHEID INC.
7.5.8.1. Company Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. HOLOGIC, INC.
7.5.9.1. Company Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. SIEMENS HEALTHCARE GMBH
7.5.10.1. Company Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic Initiatives
7.5.11. F. HOFFMANN-LA ROCHE
7.5.11.1. Company Overview
7.5.11.2. Financial Performance
7.5.11.3. Product Benchmarking
7.5.11.4. Strategic Initiatives
7.5.12. QIAGEN
7.5.12.1. Company Overview
7.5.12.2. Financial Performance
7.5.12.3. Product Benchmarking
7.5.12.4. Strategic Initiatives
7.5.13. AGILENT TECHNOLOGIES INC.
7.5.13.1. Company Overview
7.5.13.2. Financial Performance
7.5.13.3. Product Benchmarking
7.5.13.4. Strategic Initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers